Editorial Yellow fever: a major threat to public health

The world's largest fractional-dose vaccination campaign for yellow fever started on Jan 25 in Brazil, with the support of WHO. The campaign attempts to avoid the urban transmission cycle, not seen in the country since 1942. 33 people have died due to yellow fever between Jan 14 and 23, while the number of confirmed cases in the country has reached more than 130.
Source: LANCET - Category: General Medicine Authors: Tags: Editorial Source Type: research

Related Links:

Transcripts of human endogenous retrovirus K are expressed in most breast cancers (BCs). Yellow fever vaccine 17D (YFV) expresses a protein with a closely homologous epitope. Cross-reactive immunity could hypothetically inhibit BC growth at least in women aged around 50 years at diagnosis, in whom the prognosis of BC was found to be better than that in women younger or older. A cohort of 12 804 women who received YFV in the Veneto Region, Italy, was divided into two subcohorts according to age at vaccination and followed up through the Veneto Tumor Registry. The time since vaccination until cancer incidence was cate...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Research Papers: Breast Cancer Source Type: research
(Institut Pasteur) Scientists from the Institut Pasteur, the CNRS and Sanofi Pasteur have recently developed a novel alternative method to animal testing that can be used to verify the safety of vaccines such as the yellow fever vaccine. This original approach is based on the development of an in cellulo device using a 3D culture model, the 'BBB-Minibrain'. A patent application has been filed by the Institut Pasteur and Inserm. The results of this research were published in the journal Biologicals in May 2018.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
amballerie The recent resurgence of yellow fever virus (YFV) activity in the tropical regions of Africa and South America has sparked renewed interest in this infamous arboviral disease. Yellow fever virus had been a human plague for centuries prior to the identification of its urban transmission vector, the Aedes (Stegomyia) aegypti (Linnaeus) mosquito species, and the development of an efficient live-attenuated vaccine, the YF-17D strain. The combination of vector-control measures and vaccination campaigns drastically reduced YFV incidence in humans on many occasions, but the virus never ceased to circulate in the fo...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research
by Christiane Costa-Pereira, Ana Carolina Campi-Azevedo, Jordana Grazziela Coelho-dos-Reis, Vanessa Peruhype-Magalh ães, Márcio Sobreira Silva Araújo, Lis Ribeiro do Vale Antonelli, Cristina Toscano Fonseca, Jandira Aparecida Lemos, Luiz Cosme Cote Malaquias, Matheus de Souza Gomes, Laurence Rodrigues Amaral, Maria Rios, Caren Chancey, Harold Richard Persi, Jorge Marcelo Pereira, Maria de Lourdes de Sousa Maia , Marcos da Silva Freire, Reinaldo de Menezes Martins, Akira Homma, Marisol Simões, Anna Yoshida Yamamura, Roberto Henrique Guedes Farias, Alessandro Pecego Martins Romano, Carla Magda Dom...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Authors: Gallichotte EN, Baric RS, de Silva AM Abstract Dengue viruses (DENV) are mosquito-borne positive sense RNA viruses in the family Flaviviridae. The four serotypes of DENV (DENV1, DENV2, DENV3, DENV4) are widely distributed and it is estimated over a third of the world's population is at risk of infection [4]. While the majority of infections are asymptomatic, DENV infection can cause a spectrum of disease, from mild flu-like symptoms, to the more severe DENV hemorrhagic fever and shock syndrome [24]. Over the past 20 years, there have been intense efforts to develop a tetravalent live-attenuated DENV v...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Conclusions: The Brazilian AEFI registry is useful to compare the magnitude and certain characteristics of adverse events associated with mandated pediatric vaccines.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Yellow fever (YF) is a reemerging public health threat, with frequent outbreaks prompting large vaccination campaigns in regions of endemicity in Africa and South America. Specific detection of vaccine-related adverse events is resource-intensive, time-consuming, and difficult to achieve during an outbreak. To address this, we have developed a highly transferable rapid yellow fever virus (YFV) vaccine-specific real-time reverse transcription-PCR (RT-PCR) assay that distinguishes vaccine from wild-type lineages. The assay utilizes a specific hydrolysis probe that includes locked nucleic acids to enhance specific discriminat...
Source: Journal of Clinical Microbiology - Category: Microbiology Authors: Tags: Virology Source Type: research
Although a safe and effective yellow fever vaccine was developed more than 80 years ago, several issues regarding its use remain unclear. For example, what is the minimum dose that can provide immunity against...
Source: BMC Immunology - Category: Allergy & Immunology Authors: Tags: Research article Source Type: research
Vaccine responses vary by geographic location. We have previously described how HIV-associated inflammation leads to fibrosis of secondary lymph nodes (LNs) and T cell depletion. We hypothesized that other infections may cause LN inflammation and fibrosis, in a process similar to that seen in HIV infection, which may lead to T cell depletion and affect vaccine responses. We studied LNs of individuals from Kampala, Uganda, before and after yellow fever vaccination (YFV) and found fibrosis in LNs that was similar to that seen in HIV infection. We found blunted antibody responses to YFV that correlated to the amount of LN fib...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
There is marked variability in vaccine efficacy among global populations. In particular, individuals in low- to middle-income countries have been shown to be less responsive to vaccines than those from developed nations. Several factors, including endemic infections, nutrition, genetics, and gut microbiome composition, have been proposed to underlie discrepancies in vaccine response. In this issue of the JCI, Kityo et al. evaluated response to yellow fever virus vaccine, inflammation, and lymphatic tissue architecture and fibrosis in three cohorts: two from the U.S. and one from Uganda. Compared with the U.S. subjects, the...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Brazil Health | General Medicine | International Medicine & Public Health | Vaccines | Yellow Fever | Yellow Fever Vaccination